NCT07057973 The Effectiveness of Preoperative Iron Therapy in Improving Anemia After Multi-level Lumbar Fusion in the Elderly
| NCT ID | NCT07057973 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Ferric Carboxymaltose |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-07-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Preoperative iron therapy has important value in improving the outcomes after lumbar fusion surgery, but there is significant heterogeneity in both domestic and international studies. International studies provide high-level evidence-based evidence for intravenous iron, but lack spinal surgery-specific data; domestic studies focus on the comparison of iron types and the improvement of clinical practice, but high-quality evidence is still insufficient. At present, there are still few studies on preoperative iron therapy in the field of spinal surgery, especially its specific impact on the prognosis of patients after lumbar fusion surgery is still unclear. Therefore, it is particularly important to study the preoperative iron supplementation regimen for lumbar fusion surgery to improve the efficacy and safety. Through multidisciplinary collaboration and technological innovation, preoperative iron therapy is expected to become an important part of accelerated recovery after lumbar fusion surgery.
Eligibility Criteria
Inclusion Criteria: * All patients underwent multi-segment lumbar spine surgery; * IDA patients aged 65 years or older (male: Hb \< 120g/dL; female: Hb \< 110g/dL); * All patients completed the relevant questionnaire survey; Exclusion Criteria: * Age less than 65 years old; * Previous surgery for spinal tumors, trauma or infection; * Inflammatory or immune diseases (such as rheumatoid arthritis or systemic lupus erythematosus), acute kidney injury, progressive cancer and porphyria cutanea tarda); * Non-adjacent segment surgery; * History of allergy to ferric carboxymaltose or any intravenous iron preparations, asthma, atopic dermatitis or allergy; * Decompensated cirrhosis and microcytic anemia; * Incomplete clinical data;
Frequently Asked Questions
Who can join the NCT07057973 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 90 Years, studying Ferric Carboxymaltose. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07057973 currently recruiting?
Yes, NCT07057973 is actively recruiting participants. Visit ClinicalTrials.gov or contact Xuanwu Hospital, Beijing to inquire about joining.
Where is the NCT07057973 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07057973 clinical trial?
NCT07057973 is sponsored by Xuanwu Hospital, Beijing. The trial plans to enroll 100 participants.